ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- You have advanced small cell lung cancer, gastrointestinal/pancreatic neuroendocrine cancer, high-grade prostate neuroendocrine cancer, or ependymoma neuroendocrine cancer that has come back or not responded to at least one prior treatment
- Your cancer must show DLL3 protein on a biopsy sample
- You are able to do daily activities with little to no help (ECOG score 0 or 1)
- You have not received a DLL3-targeting CAR T therapy or other gene-modified cell therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Hear when a new Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.